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Abstract
Background and aims: Osteoprotegerin (OPG) is a competitive inhibitor of the differentiation and activity of osteoclasts, which inhibits the 
final stages of osteoclast formation and induces its apoptosis. In addition, OPG is considered as one of the most important candidate genes 
in the pathogenesis of bone diseases such as osteoporosis and idiopathic hyperphosphatasia. The G354A (Cys87Tyr) mutation in the OPG 
gene leads to idiopathic hyperphosphatasia. This mutation is probably related to osteoporosis. The purpose of this study was to investigate 
the presence of G354A (Cys87Tyr) in women with osteoporosis in Chaharmahal and Bakhtiari province.
Methods: In this descriptive-analytical study, the bone mineral density (BMD) of the femoral neck and lumbar spine of women referring to 
Shahrekord bone densitometry centers was measured by the X-ray absorptiometry technique in 2013-2014. Based on T-scores, people with 
osteoporosis were identified and 70 patients were enrolled in the study after receiving their consent. Finally, DNA was extracted from blood 
samples, amplified by polymerase chain reaction (PCR) technique, and sequenced by DNA sequencing method.
Results: After DNA extraction from the blood, the quality and quantity were determined by gel electrophoresis and spectrophotometry, 
respectively. Then, the gene was amplified by the PCR method and the product was detected by gel electrophoresis, followed by sequencing 
the samples to investigate the presence of the mutation. Eventually, genotypes associated with Cys87Tyr mutation were not observed in 
the studied population.
Conclusion: In the present study, the G354A (Cys87Tyr) mutation associated with idiopathic hyperphosphatasia was not found in women 
with osteoporosis.
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Introduction 
Osteoporosis is regarded as a skeletal disease that is 
associated with decreased bone mass and increased risk 
of bone fragility (1). Previous evidence indicates that on 
average, over 50% of women over the age of 50 are at the 
risk of osteoporotic fractures (2). 
The key mechanism that regulates the rate of bone 
formation and resorption (regeneration) is related to the 
RANKL/RANK/OPG pathway. In fact, RANKL, its 
receptor (RANK), and its decoy receptor osteoprotegerin 
(OPG) play a key role in regulating bone regeneration. 
This pathway is based on the increased differentiation of 
osteoclasts through the binding of the RANKL ligand to its 
membrane receptor (RANK) on mononuclear osteoclast 
precursors. This increased differentiation of osteoclasts 
by RANKL is inhibited by the OPG that is produced by 
osteoblasts (3).
In the bone microenvironment, the ratio of RANKL 
to OPG indicates the activation rate of the osteoclasts. In 
addition, the normal activation of osteoclasts is due to the 
physiological degradation of bone in bone regeneration 
while the excessive activity of osteoclasts leads to various 
bone diseases including osteoporosis (4). 
According to some studies, many mutations and single-
nucleotide polymorphisms in the human OPG gene are 
associated with osteoporosis or osteoporosis phenotypes, 
including osteoporotic fractures and decreased bone 
mineral density (BMD), as well as other metabolic and 
bone regeneration-related diseases such as idiopathic 
hyperphosphatasia (5,6). Idiopathic hyperphosphatasia is 
a rare autosomal recessive bone disease and is observed in 
young male and female children (7). There is a considerable 
phenotypic variation from severe to mild in the affected 
people. 
Generally, babies are normal at birth, but they gradually 
exhibit bone radiological changes, bone fractures, bone 
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pain, and skull enlargement, as well as the increased risk of 
pathologic fractures and non-bone changes (8).
Biochemical analyses represent that there is a significant 
increase in the serum alkaline phosphatase activity, which 
results in an increase in the rate of bone regeneration (6,8). 
Previous research demonstrates that the disease is mainly 
due to the mutation in the OPG coding gene. In this 
disease, the loss of normal OPG function leads to increased 
bone regeneration (6). The mutation G354A (Cys87Tyr) 
located in exon 2 of the OPG gene leads to idiopathic 
hyperphosphatasia possibly due to the degradation of the 
sulfide bonds in the second cysteine-rich domain  II (the 
second most effective domain in interacting with the 
ligand) OPG and the reduction of cysteine amino  acids (6). 
Moreover, the loss of the disulfide bond apparently 
leads to the loss of the natural structure of OPG and the 
disruption of OPG binding to its ligand (RANKL). The 
resulting changes in protein structure may also affect 
protein stability (6, 9).
This homozygous missense mutation has been 
investigated in different countries and was observed in 
a six-year-old boy with idiopathic hyperphosphatasia 
in Argentina (6). However, another recessive missense 
mutation (C65R) in cysteine residue of exon 2 was 
reported in a girl in Turkey (6). Although the BMD of their 
parents, who were the carrier of these mutations, were not 
assessed, the heterozygous form of Cys87Tyr mutation may 
be associated with BMD. 
Therefore, the current study sought to evaluate the 
presence of G354A mutation (Cys87Tyr) for the first time 
in women with osteoporosis in Chaharmahal and Bakhtiari 
province. 
Materials and Methods 
In this descriptive-analytical study, the BMD of the lumbar 
spine and the femoral neck was measured in women 
referring to Shahrekord bone densitometry centers by the 
X-ray absorptiometry method and Hologic QDR device 
(Germany) in 2013-2014. 
Patients with a history of corticosteroid use, ovariectomy 
or early ovarian failure, thyroid disease, impaired calcium 
absorption, as well as digestive and kidney diseases were 
excluded from the study.
People with osteoporosis were identified based on T-score, 
70 of whom were enrolled in the study after completing the 
consent form for participation in the study. 
For genetic assessments, a 5-mL complete blood 
sample of each participant was collected by the simple 
sampling method and then poured into a tube containing 
the anticoagulant ethylenediaminetetraacetic acid. The 
genomic DNA was extracted from the blood samples using 
the protocol of the CinnaGen kit. The concentration of 
the extracted DNA and its quality were determined using 
a spectrophotometer and agarose gel electrophoresis, 
respectively. 
The desired range of the OPG gene was amplified 
using the primers designed by Gene Runner software. 
Further, the sequences of forward and reverse primers 
were 5’-GTACAGCAAAGTGGAAGA-3’ and 
5’-CTCCTAAACTGTCACAACTA-3’, respectively. The 
polymerase chain reaction (PCR) solution included 2.5 μL 
buffer 10X, 1.5 μL 50 mM MgCl2, 1 μL 40 mM dNTP 
Mix, 0.7 μL forward primer 10 pmol/mL, 0.2 μL Taq 
polymerase 5 U/μL, 3.2 μL template DNA, and ddH2O 
to a final reaction volume of 25 μL. PCR reactions were 
performed using the thermocycler model (ASTEC, PC818 
Japan) with the thermal conditions as follows: 95°C for 5 
minutes, followed by 36 cycles of 94°C, 45°C, and 72°C for 
30, 30, and 30 seconds, respectively, with a final extension 
at 72°C for 10 minutes.
The length of the amplified fragment was 308 bp and 
then the fragment was observed by gel electrophoresis. 
Finally, the samples were sequenced by Genfanavaran 
Company to investigate the presence of a mutation.
Results 
People with a T-score equal to -2.5 or higher are at the risk 
of osteoporosis. Based on this criterion, 70 patients with 
osteoporosis were identified and then enrolled in the study 
after receiving their consent. After PCR amplification, the 
product size was examined on the agarose gel. The image of 
the PCR products is shown in Figure 1.
The samples were sequenced to determine the presence 
of the G354A (Cys87Tyr) mutation and the sequencing 
results for all 70 patients showed normal allele while 
demonstrating no mutation (Figure 2).
Discussion
Osteoporosis is a multifactorial (multigenic and multi-
environmental) disease in postmenopausal women (1). 
It is characterized by an increase in fracture risk and 
a reduction in bone density (2). Genetic factors play 
important roles in the pathogenesis of osteoporosis and 
reduction of BMD. The examples of these genetic factors 
are vitamin D receptor, collagen 1a1, and OPG genes (10-
12). It was suggested that the sequence variation in genes 
other than OPG have a substantial impact on BMD, bone 
regeneration rate, and osteoporosis (13). Furthermore, the 
OPG gene is associated with osteoporosis or osteoporosis 
phenotypes such as osteoporotic fractures and decreased 
BMD, along with other metabolic and bone regeneration-
related diseases such as idiopathic hyperphosphatasia 
(4,6,13). This gene contains various polymorphic sites. 
The association of some of these polymorphic sites with 
BMD and osteoporosis was investigated in different 
races and geographical locations (13,14). Some of these 
studies show contradictory results in this regard. There 
are seven polymorphic sites (i.e., Ilu16Thr, Thr20Ilu, 
Cys87Tyr, Val104Met, Phe117Leu, Cys87Tyr, Cys65Arg) 
in exon 2 of the OPG gene (6,10,15-18). Four of them 
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were mainly studied in Chinese postmenopausal women 
and the findings confirmed their associations with BMD 
(10,15-17). Three other sites were indicated to be related to 
idiopathic hyperphosphatasia phenotypes (severe to mild 
phenotypes), including deformities and fractures in two 
girls and one boy in Argentina and Turkey (6). One of these 
polymorphic sites (Phe117Leu), which was observed in an 
idiopathic hyperphosphatasia girl in Argentina, was also 
studied in Chinese women and claimed to be associated 
with BMD (18). The Cys87Tyr site, which was related 
to severe phenotype in an idiopathic hyperphosphatasia 
boy with homozygote form (Tyr/Tyr), may also be a good 
candidate for investigating the possible association with 
BMD. Also, sex may have an effect in association studies as 
with the T950C polymorphism in Swedish women and men 
populations (19,20). Considering the above-mentioned 
explanations, it was decided to study the presence of 
G354A mutation (Cys87Tyr) in women with osteoporosis 
in Chaharmahal and Bakhtiari Province.
Due to the importance of OPG in bone metabolism, the 
heterozygote form of this site (Cys/Tyr) could be found in 
osteoporotic women. However, the findings of this study 
showed only one homozygote phenotype (Cys/Cys), while 
the carrier of this mutation was not found in this group. 
This is consistent with the previous study in which it is 
considered a rare change in the exon 2 of OPG. Although 
it was reported that the G354A (Cys87Tyr) change is a rare 
mutation, the presence of this mutation was investigated 
in the healthy group. Moreover, no carrier of this mutation 
was reported in this group in the current study (data not 
available). 
However, given that a wide variety of genetic and 
environmental factors play a role in the development 
of bone diseases such as osteoporosis and idiopathic 
hyperphosphatasia and limited research is available on this 
mutation, future studies are recommended to investigate 
the presence of this mutation in people (men and women) 
with osteoporosis and other bone diseases. Moreover, the 
mutation in other genes like RANK, CSF1, and TM7SF4 
related to idiopathic hyperphosphatasia (7,8) can also be 
evaluated in osteoporotic males and females. 
Conclusion
In our study, the G354A (Cys87Tyr) mutation associated 
with idiopathic hyperphosphatasia was not observed in 
women with osteoporosis in Chaharmahal and Bakhtiari 
Province. Accordingly, further studies on this mutation in 
OPG and other genes such as RANK, CSF1, and TM7SF4 
are recommended to be conducted on people (men and 
women) with bone diseases.
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